Business Context and Reporting Period
This Form 6-K filing by Ascentage Pharma Group International covers the month of April 2026. The report discloses a corporate administrative update regarding the company's principal place of business in Hong Kong.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate event and does not contain financial statements.
Material Changes
On April 1, 2026, the Company announced a change to its principal place of business in Hong Kong. No financial material changes were reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The sole purpose of this filing is to furnish the announcement regarding the change of address.
Key Facts for Investors
- The Company changed its principal place of business in Hong Kong effective April 1, 2026.
- This filing does not include financial performance data or forward-looking statements.
- The announcement is attached as Exhibit 99.1 to this report.